CIEMAR complete with 500 patients
The European-wide CIRSE registry on microwave ablation in patients with colorectal liver metastases, CIEMAR, started patient enrolment in September 2019. After more than three years of patient enrolment and data collection, the study reached its milestone of 500 patients enrolled in January 2023. Thanks to the very dedicated site personnel of the centres participating in CIEMAR, the patient target could be achieved despite the difficulties in patient recruitment and data entry due to the pandemic.
CIEMAR aims to observe the real-life use of Emprint microwave ablation treatment in patients with colorectal liver metastases across Europe, and its primary objective is to assess the effectiveness of microwave ablation performed with the Emprint or Emprint HP device in controlling colorectal metastatic tumours in the liver.
CIEMAR in follow-up
With the end of patient enrolment in January 2023, follow-up data inclusion will continue until January 2026. The current focus is to continue collecting high-quality, long-term follow-up data to address study endpoints.
30 centres from 11 European countries enrolled patients in CIEMAR. The six countries with the largest number of enrolled patients are the Netherlands (126 patients), Italy (121 patients), Germany (80 patients), Turkey (43), Norway (33 patients) and North Macedonia (30 patients). The rest of the countries (n=5) enrolled fewer than 26 patients each.
CIEMAR at ECIO and at E-AHPBA 2023
CIEMAR baseline, treatment and safety early data were presented at this year’s European Conference on Interventional Oncology, ECIO in Stockholm by the CIEMAR Steering Committee Co-chairperson and Principal Investigator, Prof. Philippe Pereira from the SLK Kliniken GmbH Heilbronn in Germany under the title ‘Short-term results of CIEMAR, the prospective, observational study on patients with colorectal liver metastases treated with microwave ablation in Europe.’ The presentation is available on demand here.
Similar data will also be presented as a talking poster by the CIEMAR Principal Investigator, Dr. Åsmund Avdem Fretland from the Oslo University Hospital in Norway at the European-African Hepato-Pancreato-Biliary Association 2023 that will take place on 6-9 June in Lyon, France.
If you would like to receive further information on CIEMAR, please contact: